Detalhe da pesquisa
1.
Lanreotide vs octreotide LAR for patients with advanced gastroenteropancreatic neuroendocrine tumors: An observational time and motion analysis.
J Oncol Pharm Pract
; 25(6): 1425-1433, 2019 Sep.
Artigo
em Inglês
| MEDLINE | ID: mdl-30924737
2.
The development of a prediction tool to identify cancer patients at high risk for chemotherapy-induced nausea and vomiting.
Ann Oncol
; 28(6): 1260-1267, 2017 Jun 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-28398530
3.
A randomized, double-blind, phase II, exploratory trial evaluating the palliative benefit of either continuing pamidronate or switching to zoledronic acid in patients with high-risk bone metastases from breast cancer.
Breast Cancer Res Treat
; 155(1): 77-84, 2016 Jan.
Artigo
em Inglês
| MEDLINE | ID: mdl-26643085
4.
What is a new drug worth? An innovative model for performance-based pricing.
Eur J Cancer Care (Engl)
; 24(3): 313-20, 2015 May.
Artigo
em Inglês
| MEDLINE | ID: mdl-25256668
5.
A comparison of toxicity and health care resource use between eribulin, capecitabine, gemcitabine, and vinorelbine in patients with metastatic breast cancer treated in a community oncology setting.
J Oncol Pharm Pract
; 21(3): 170-7, 2015 Jun.
Artigo
em Inglês
| MEDLINE | ID: mdl-24620009
6.
Preference weights for chemotherapy side effects from the perspective of women with breast cancer.
Breast Cancer Res Treat
; 142(1): 101-7, 2013 Nov.
Artigo
em Inglês
| MEDLINE | ID: mdl-24129976
7.
Clinical trial design in biosimilar drug development.
Invest New Drugs
; 31(2): 479-87, 2013 Apr.
Artigo
em Inglês
| MEDLINE | ID: mdl-23161336
8.
Clinical outcomes of women with metastatic breast cancer treated with nab-paclitaxel: experience from a single academic cancer centre.
Curr Oncol
; 20(1): 24-9, 2013 Feb.
Artigo
em Inglês
| MEDLINE | ID: mdl-23443761
9.
Development and validation of a prediction index for hand-foot skin reaction in cancer patients receiving sorafenib.
Ann Oncol
; 23(8): 2103-2108, 2012 Aug.
Artigo
em Inglês
| MEDLINE | ID: mdl-22228446
10.
Prospective validation of risk prediction indexes for acute and delayed chemotherapy-induced nausea and vomiting.
Curr Oncol
; 19(6): e414-21, 2012 Dec.
Artigo
em Inglês
| MEDLINE | ID: mdl-23300365
11.
An economic analysis comparing health care resource use and cost of dose-dense methotrexate, vinblastine, doxorubicin, and cisplatin versus gemcitabine and cisplatin as neoadjuvant therapy for muscle invasive bladder cancer.
Urol Oncol
; 39(12): 834.e1-834.e7, 2021 12.
Artigo
em Inglês
| MEDLINE | ID: mdl-34162500
12.
A randomized trial exploring the biomarker effects of neoadjuvant sequential treatment with exemestane and anastrozole in post-menopausal women with hormone receptor-positive breast cancer.
Breast Cancer Res Treat
; 119(1): 155-61, 2010 Jan.
Artigo
em Inglês
| MEDLINE | ID: mdl-19731013
13.
A randomized trial of individualized versus standard of care antiemetic therapy for breast cancer patients at high risk for chemotherapy-induced nausea and vomiting.
Breast
; 54: 278-285, 2020 Dec.
Artigo
em Inglês
| MEDLINE | ID: mdl-33242754
14.
Does confirmatory tumor biopsy alter the management of breast cancer patients with distant metastases?
Ann Oncol
; 20(9): 1499-1504, 2009 Sep.
Artigo
em Inglês
| MEDLINE | ID: mdl-19299408
15.
Nab-Paclitaxel or Docetaxel as Alternatives to Solvent-Based Paclitaxel in Metastatic Breast Cancer (Mbc): A Cost Utility Analysis from a Chinese Health Care Perspective.
Value Health
; 17(7): A642, 2014 Nov.
Artigo
em Inglês
| MEDLINE | ID: mdl-27202301
16.
Abraxane Versus Taxol For Patients with Advanced Breast Cancer: A Prospective Time and Motion Analysis from a Chinese Health Care Perspective.
Value Health
; 17(7): A737, 2014 Nov.
Artigo
em Inglês
| MEDLINE | ID: mdl-27202644
17.
Modeling the economic outcomes of immuno-oncology drugs: alternative model frameworks to capture clinical outcomes.
Clinicoecon Outcomes Res
; 10: 139-154, 2018.
Artigo
em Inglês
| MEDLINE | ID: mdl-29563820
18.
Prevention and management of chemotherapy-induced diarrhea in patients with colorectal cancer: a consensus statement by the Canadian Working Group on Chemotherapy-Induced Diarrhea.
Curr Oncol
; 14(1): 13-20, 2007 Feb.
Artigo
em Inglês
| MEDLINE | ID: mdl-17576459
19.
Cost-utility analysis of chemotherapy using paclitaxel, docetaxel, or vinorelbine for patients with anthracycline-resistant breast cancer.
J Clin Oncol
; 17(10): 3082-90, 1999 Oct.
Artigo
em Inglês
| MEDLINE | ID: mdl-10506603
20.
Economic analyses of toxicity secondary to anthracycline-based breast cancer chemotherapy.
Eur J Cancer
; 31A(13-14): 2174-80, 1995 Dec.
Artigo
em Inglês
| MEDLINE | ID: mdl-8652238